Invivyd为LIBETY III期试验的首批参与者接种了VYD 2311单独接种以及VYD 2311与Covid-19疫苗联合接种的健康成人;预计2026年第三季度将发布总体数据，以伴随来自重大衰退研究的预期数据

2026-06-09 19:06

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19 vaccine.
Depending on study recruitment rate, Invivyd expects to report topline data from LIBERTY in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trial.
Prior exploration of monoclonal antibody (mAb) interaction with vaccine published here suggests a minimal clinical consequence to a similar interaction today, but could provide data to aid in potential product labelling language, if approved. This earlier work demonstrated an expected, modest reduction in vaccine-induced neutralizing antibody titers from co-administration of mAb and vaccine, in seronegative populations, with T Cell and other vaccine-induced metrics minimally changed.
LIBERTY is part of Invivyd's broader REVOLUTION clinical program, including DECLARATION, designed to characterize the profile of mAb-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans